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Abstract
Background: Patients with inflammatory bowel disease 
(IBD) have a higher risk of infection and are frequently not up 
to date with their immunizations. Objectives: This study aims 
to review vaccination status and evaluate whether age, dis-
ease type, or treatment regimen could predict the absence 
of seroprotection against selected vaccine-preventable in-
fection in adults with IBD. Methods: Cross-sectional study us-
ing questionnaire, immunization records review, and assess-
ment of tetanus-specific, varicella-specific, and measles-spe-
cific immunoglobulin G concentrations. ClinicalTrials.gov: 
NCT01908283. Results: Among the 306 adults assessed (me-
dian age 42.7 years old, 70% with Crohn’s disease, 78% re-
ceiving immunosuppressive treatment), only 33% had an im-
munization record available. Absence of seroprotection 
against tetanus (6%) was associated with increasing age and 
absence of booster dose; absence of seroprotection against 
varicella (1%) or measles (3%) was exclusively observed in 
younger patients with Crohn’s disease. There was no statisti-
cally significant difference in immunoglobulin concentra-
tions among treatment groups. Although vaccinations are 
strongly recommended in IBD patients, the frequencies of 
participants with at least 1 dose of vaccine recorded were low 
for nearly all antigens: tetanus 94%, diphtheria 87%, pertussis 
54%, poliovirus 22%, measles-mumps-rubella 47%, varicella-
zoster 0%, Streptococcus pneumoniae 5%, Neisseria meningit-
idis 12%, hepatitis A 41%, hepatitis B 48%, human papilloma-
virus 5%, and tick-borne encephalitis 6%. Conclusions: Al-
though many guidelines recommend the vaccination of IBD 
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patients, disease prevention through immunization is still 
often overlooked, including in Switzerland, increasing their 
risk of vaccine-preventable diseases. Serological testing 
should be standardized to monitor patients’ protection dur-
ing follow-up as immunity may wane faster in this popula-
tion. © 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
As the immune system of patients with inflammatory 
bowel disease (IBD) is altered, their vulnerability to infec-
tions is greater [1–3]. Several international groups of ex-
perts have hence issued structured recommendations on 
vaccination in immunocompromised hosts and IBD pa-
tients [4–9], recently reviewed in this journal [10]. Unfor-
tunately, a number of studies have pointed out that the 
vaccination status of IBD patients is suboptimal [11–15], 
and that their immune responses to nearly all vaccina-
tions can be impaired [16], in particular in those under 
immunosuppressive treatment [17]. Our aim was to doc-
ument the vaccination status in Swiss adults with IBD and 
identify whether age, disease type, or treatment regimen 
could predict the absence of seroprotection against se-
lected vaccine-preventable infections.
Materials and Methods
This cross-sectional study was nested in a phase IV multicenter 
study evaluating the safety and immunogenicity of the 13-valent 
pneumococcal conjugate vaccine in 306 adults with IBD [18]. Par-
ticipants from 4 regions in Switzerland (Bern, Geneva, Neuchatel, 
and Vaud) were included as previously described and provided 
their written informed consent. Temporary exclusion criteria were 
pregnancy, current IBD flare pregnancy, pneumococcal immuni-
zation in the previous 5 years, and influenza immunization in the 
previous 4 weeks [18]. The protocol was approved by the Ethics 
Committee of all participating institutions (CER 12-211), and the 
study was conducted in compliance with the Declaration of Hel-
sinki.
Two questionnaires were completed at inclusion collecting de-
tails on participants’ disease and treatment (306 questionnaires 
completed) and querying previous history of vaccine-preventable 
infections and/or vaccinations (299 questionnaires completed), 
including review of immunization records (101 records available). 
Blood was collected from all 306 participants at inclusion; tetanus-
specific, varicella-specific, and measles-specific immunoglobulin 
G (IgG) concentrations were measured using ELISA on the plat-
form DSX® (Dynex® Technologies, Chantilly, VA, USA). The cut-
offs for defining seroprotective concentration against tetanus, var-
icella, and measles were set as 100 IU/L, 50 IU/L, and 150 IU/L, 
respectively. These were experimentally defined as the lowest con-
centration associated with the presence of neutralizing antibodies 
in a series of independent sera from healthy subjects (unpublished 
data).
Mann-Whitney tests were used for comparison of IgG concen-
tration among gender and diagnostic groups. Kruskal-Wallis tests 
were used for comparison among participants’ age (18–35 years 
old, 35–50 years old, 50–65 years old, and above 65 years old), re-
gion (Bern, Geneva, Neuchatel, and Vaud), and treatment groups 
(no immunosuppression, immunosuppression without anti-TNF, 
and immunosuppression with anti-TNF), followed by Mann-
Whitney tests for comparisons between subgroups. All analyses 
were 2-sided and performed using Stata 13® (StataCorp, College 
Station, TX, USA), and p < 0.05 was considered statistically sig-
nificant. Bonferroni adjustment was used for multiple compari-
sons. ClinicalTrials.gov identifier: NCT01908283.
Table 1. Participant characteristics
Participants (n = 306)
Sex 158 female (52%)
148 male (48%)
Age, years Median 42.7, IQR, 29.4–52.5
Diagnostic 213 Crohn’s disease (70%)





5-Aminosalicylic acid 67 (22%)
Sulfasalazine 2 (1%)
Topical corticosteroids 5 (2%)
Vedolizumab 26 (9%)
Immunosuppressive treatment 235 (77%)







Anti-TNF-alpha agents 155 (51%)a
Infliximab 114 (37%)
Adalimumab 26 (9%)
Certolizumab pegol 9 (3%)
Golimumab 7 (2%)
Serology results
Anti-tetanus IgG, IU/L Median 1,080, IQR, 516–2,098
Anti-varicella IgG, IU/L Median 1,485, IQR, 1018–2,078
Anti-measles IgG, IU/L Median 3,866, IQR, 943-11–407
Anti-TNF, antitumor necrosis factor; IQR, interquartile range; 
IgG, immunoglobulin G. a One patient was receiving both adalim-
umab and certolizumab pegol.
Seroprotection against Vaccine-




A total of 306 participants aged 18.0–92.5 years (me-
dian 42.7) were assessed (Table  1). The majority had 
Crohn’s disease (70%) and was receiving an immunosup-
pressive treatment (78%), mostly anti-TNF agents (51%) 
[18]. Only 101 participants had an immunization record 
available (Table 2); their status was compared to the Swiss 
recommendation (summarized in Table 3). According to 
the questionnaire, approximately a third of the cohort 
(112/299) had been immunized against influenza during 
the preceding winter and 61% (186/299) had received the 
influenza vaccine at least once in their life. Among those, 
nearly half (86/186) were immunized yearly.
Seroprotection rates against tetanus, varicella, and 
measles were high (Fig.  1). Nearly all participants 
(288/306, 94%) were seroprotected against tetanus. Teta-
nus-specific IgG concentration was the highest in the 35- 
Table 2. Vaccination status of Swiss IBD patients




Tetanus 94 Doses, n: median 5 (IQR: 3–6)
Delay since last dose: median 11.5 yr (IQR: 5.3–23.5)
Diphtheria 87 Doses, n: median 5 (IQR: 3–6)
Delay since last dose: median 10.5 yr (IQR: 5.2–23.1)
Pertussis 54 Doses, n: median 4 (IQR: 3–4)
Delay since last dose: median 25.9 yr (IQR: 13.1–40)
Poliovirus 22 Doses, n: median 1 (IQR: 1–4)
Delay since last dose: median 10.4 yr (IQR: 7.1–23.5)
Varicella-zoster 0 Comment: neither varicella nor zoster vaccine
Measles-mumps-rubella 47 Doses, n: 1 dose in 17/47 participants (36%) and 2 to 3 doses in 30/47 participants (64%)
Pneumococcus 5 Vaccine type: PPSV23 in 5/5 participants (100%), no PCV
Doses, n: 1 dose in 4/5 participants (80%), 2 doses in 1/5 participants given 13 years apart 
(20%)
Meningococcus 12 Vaccine type: MCV-C in 10/12 participants (83%), MPV-ACWY in 1 participant (8%), 
MCV-ACWY in 1 participant (8%)
Doses, n: 1 dose in 11/12 participants (92%), 2 doses (of MCV-C) in 1/12 participant 
(8%)
Hepatitis A 41 Doses, n: 1 dose in 13/41 participants (32%), 2 doses in 15/41 participants (37%), ≥3 
 doses in 13/41 (32%)
Hepatitis B 48 Doses, n: 1 dose in 2/48 participants (4%), 2–3 doses in 35/48 (73%), >3 doses in 11/48 
(23%; 4 doses in 7/48, 5 doses in 2/48, 6 doses in 1/48, and 7 doses in 1)
Human papillomavirus 5 Doses, n: 3 doses in 5/5 participants (100%)
Tick-borne encephalitis 6 Doses, n: 3 doses in 5/6 participants (83%), 2 doses in 1/6 participants (17%)
Yellow fever 7 Doses, n: 1 dose in 5/7 participants (71%), 2 doses in 2/7 participants (29%)
Typhoid 9 Doses, n: 1 dose in 6/9 participants (67%), 2 doses in 1/9 participants (11%), 3 doses in 
2/9 participants (22%)
Rabies 2 Doses, n: 2 doses in 1/2 participants (50%), 6 doses in 1/2 participants (50%)
Swiss recommendations for vaccination in IBD patients are summarized in Table 3. IBD, inflammatory bowel disease; IQR, inter-
quartile range; MCV-ACWY, meningococcal conjugate vaccine against serogroups A, C, W, and Y; MCV-C, meningococcal conjugate 
vaccine against serogroup C; MPV-ACWY, meningococcal polysaccharide vaccine against serogroups A, C, W, and Y; PCV, pneumo-
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to 50-year-old group (p = 0.003, compared with the rest) 
and the lowest in the >65-year-old group (p < 0.001, com-
pared with the rest). Overall, tetanus-specific IgG con-
centrations were slightly lower in participants with 
Crohn’s disease (p = 0.09, compared with participants 
with ulcerative colitis). There was no difference among 
treatment and region groups; 5 of the 18 nonseroprotect-
ed participants were not receiving any immunosuppres-
sive treatment. Among the 18 nonseroprotected partici-
pants, only 3 had an immunization record available, and 
their last tetanus doses documented were nearly 30 years 
before inclusion.
A quarter of the participants either did not recall pre-
vious history of chickenpox disease (19%) or believed 
they never had it before (9%). Nevertheless, 99% of par-
ticipants were seroprotected against varicella. There was 
no statistically significant difference in varicella-specific 
IgG concentration between the gender, treatment, age, 
region, and disease groups. The 2 nonseroprotected par-
ticipants were in their 30s and had Crohn’s disease.
Nearly all participants (97%) were seroprotected 
against measles. A third of the participants (32%) recalled 
having measles disease and had significantly higher IgG 
concentration. Higher measles-specific IgG concentra-
tion was associated with increasing age (Fig. 1); the level 
was the highest in the >65-year-old group (p < 0.001, 
compared with the rest). All the nonseroprotected par-
ticipants were <30 years old and had Crohn’s disease; 
most of them (7/10) were receiving immunosuppressive 
treatment. Only 2 of them had an immunization record 
available, with 1–2 doses of measles-mumps-rubella doc-
umented. There was no statistically significant difference 
in measles-specific IgG concentration between the region 
groups.
Discussion
Although numerous immunization guidelines exist 
[4–9], this cross-sectional study of over 300 adults with 
IBD suggests that there are many missed opportunities 
for disease prevention through vaccination, putting these 
patients at risk for infection. Only a third of the partici-
pants had an immunization record available, with low 
vaccination rates for nearly all pathogens, emphasizing 
the room for improvement. This is in line with previous 
reports in IBD patients from other regions, revealing that 
physicians’ and patients’ compliance with the published 
recommendations remains poor [19, 20]; vaccinations 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 1. Serologic status of adult IBD patients against tetanus, varicella, and measles, by age, disease, and treatment. 
*p < 0.05; **p < 0.01; ***p < 0.001. IBD, inflammatory bowel disease; IgG, immunoglobulin G; IU/L, interna-
tional unit per liter; TNF, tumor necrosis factor; yo, years old.
Seroprotection against Vaccine-
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recommendations for this population [21]. This may be 
attributed to numerous factors [11–15], such as fear of 
vaccine-induced adverse events and/or of interference of 
treatment on vaccine responses [22, 23].
At least 1 dose of tetanus-containing vaccine was doc-
umented on nearly all vaccination records. However, 
most participants were not up to date, with insufficient 
number of doses, and long delays since the last vaccine 
dose recorded, whereas boosters are recommended every 
10 years in immunocompromised patients [4]. Eighteen 
participants had undetectable tetanus serology, in whom 
a soiled wound would carry significant risk. Our data sug-
gest that this was probably due to waning immunity with 
age, in the absence of booster dose. However, both the 
disease and treatment likely had an impact as well, given 
the overall lower seroprotection rate and antitetanus IgG 
concentration compared to those reported in the healthy 
population [24]. Interestingly, 5 nonseroprotected par-
ticipants were not receiving any immunosuppressive 
treatment, highlighting the need for serological monitor-
ing regardless of the treatment regimen.
An alarming low number of participants were vacci-
nated against hepatitis virus A and B; among them, a high 
proportion had received more vaccine doses than usually 
indicated, suggesting that they were probably “nonre-
sponders.” Additionally, only few participants were vac-
cinated against the human papillomavirus, whereas this 
vaccine is highly recommended in this population, given 
their higher risk of HPV-related malignancy [7, 25]. Only 
5% of the participants with an available vaccination re-
cord had received a pneumococcal vaccine. IBD patients 
have an increased risk of pneumococcal infection [2, 26–
28]; the safety and immunogenicity of the pneumococcal 
conjugate vaccine have now been established in adults 
with IBD, regardless of their underlying treatment [18, 
29], and therefore the use of this vaccine should be strong-
ly promoted in this population. Annual vaccination 
against influenza virus is also highly recommended to 
prevent hospitalization and secondary infection with 
pneumococcus; however, less than half of the participants 
surveyed were following this recommendation. All those 
facts strongly advocate for systematically updating the 
IBD patients’ immunization status and emphasize the im-
portance of monitoring vaccine responses in this popula-
tion.
Varicella and measles infections have a higher risk of 
complications in immunocompromised patients [30], in-
cluding those with IBD [31], with mortality rates up to 7% 
and 40–70%, respectively [32–34]; Janus kinase inhibitor 
in particular greatly increases the risk of herpes zoster [35, 
36]. Guidelines recommend serological testing at IBD di-
agnosis, with immunization updating, and postexposure 
prophylaxis in case of contact [7]. Our study shows that 
nearly all participants were seroprotected against both in-
fections. In Switzerland, varicella vaccination is recom-
mended in all individuals aged ≥11 years who never had 
chickenpox. As a result, the virus circulates in the com-
munity, enabling seroprotected individuals to boost their 
immunity regularly. This may explain why we found such 
high varicella-specific antibody concentration across all 
age groups. Our results may not be generalizable to pop-
ulations with lower circulation rate of the varicella virus. 
Nevertheless, 2 participants were not seroprotected and 
were unaware of their risk of severe infection if exposed 
to varicella. Our results also confirm prior assumption 
that questioning patients on previous history of disease is 
not reliable enough [37] since a quarter of the seropro-
tected participants could not recall having had chicken-
pox previously. As for measles, universal vaccination 
started in the 1960s, and therefore nearly all individuals 
aged ≥50 had presumably been in contact with the virus 
during childhood. This might explain why in our study 
the individuals aged >65 years old had the highest anti-
measles antibody concentration. All the nonseroprotect-
ed participants were <30 years old. Previous vaccination 
was documented in the 2 participants with an available 
vaccination record. Measles infections could potentially 
be fatal in these 10 nonseroprotected patients, most of 
them having immunosuppressive treatment. Our data, in 
line with previous studies from other regions [38, 39], 
suggest that serological testing should be standardized in 
all IBD patients.
In conclusion, disease prevention in immunocompro-
mised patients through immunization is often over-
looked, but is indeed needed; serological testing should 
be standardized to monitor patients’ protection during 
follow-up as immunity may wane faster in this popula-
tion. Temporary withholding of immunomodulating 
treatment is recommended during an infectious illness, 
which could have an impact on disease activity. There-
fore, by preventing infections, vaccines also indirectly 
spare IBD flaring [2, 7]. Awareness raising campaigns 
must be organized to promote the systematic monitoring 
of specific disease immunity status and subsequent vac-
cination strategies among the IBD population, regardless 
of the treatment regimen [19, 20]. Campaigns should 
convince physicians and patients that vaccines are safe 
even for patients with immune-mediated inflammatory 
diseases, in whom they do not trigger disease flare, and 
that protection is likely to be reached, especially when 
Pittet et al.Digestion8
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vaccination is performed during periods of reduced im-
mune suppression [6], even if vaccine immunogenicity 
might be slightly attenuated due to immunosuppression 
[40–46].
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